Press release
Pulmonary Arterial Hypertension Market is expected to show growth from 2024 to 2030, reported by Maximize Market Research
Pulmonary Arterial Hypertension Market
Pulmonary Arterial Hypertension Market Overview
The Pulmonary Arterial Hypertension (PAH) market is growing due to rising awareness, early diagnosis, and an expanding patient base. Companies are capitalizing on patent expirations to offer affordable generics. PAH prevalence is increasing, with 500 to 1000 new U.S. cases annually, particularly affecting women aged 30 to 60. Idiopathic or genetic factors account for 15-20% of cases. The rising prevalence of Pulmonary Arterial Hypertension (PAH) is significantly driving the growth of the PAH market. Characterized by elevated blood pressure in lung arteries, diagnosed cases have surged due to increased awareness, improved diagnostic methods, and changing lifestyles. This expanding patient pool demands enhanced healthcare solutions, prompting investments in pharmaceuticals, therapies, and medical devices for PAH management. Companies are focused on research and development to introduce innovative treatments that meet this burgeoning demand.
Pharmaceutical firms are intensifying efforts to develop novel drugs, while healthcare providers are improving diagnostic and treatment infrastructures. The PAH market faces challenges such as limited treatment options, high medication costs, and complex diagnoses leading to delays in care. Low awareness among healthcare professionals and the public, adherence issues, and comorbidities further complicate management. Additionally, the competitive landscape impacts pricing and market access. Innovative therapies for pulmonary arterial hypertension (PAH) focus on novel treatments that improve efficacy and reduce side effects. Selexipag (Uptravi), an oral prostacyclin receptor agonist, exemplifies this shift, offering convenient administration compared to traditional treatments, thereby enhancing patient compliance and care in the PAH market. The major market palyers are the United Therapeutics Corporation, Gilead Sciences, Pfizer Inc., and Arena Pharmaceuticals, Etc. North America led the Pulmonary Arterial Hypertension (PAH) market in 2023, driven by a robust healthcare infrastructure, high diagnosis rates, and supportive government initiatives like the Rare Disease Act and the Orphan Drug Act. Key countries include the U.S., Canada, and Mexico. Europe is expected to experience the fastest market growth, supported by agencies like the European Medicines Agency promoting early diagnosis. Factors contributing to growth in Europe include rising chronic disease prevalence, an aging population, lifestyle changes, and environmental pollution, all of which are likely to drive demand for PAH treatments.
๐๐จ๐ฎ๐ซ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ฌ ๐๐ฎ๐ฌ๐ญ ๐ ๐๐ฅ๐ข๐๐ค ๐๐ฐ๐ :https://www.maximizemarketresearch.com/request-sample/122335/
Recent Development
February 2023- Bayer AG announced the acquisition of MyoKardia, Inc., for $1.6 billion. MyoKardia is a clinical-stage biopharmaceutical company developing a new mavacamten drug to treat PAH. Mavacamten is a cardiac myosin inhibitor that has been shown to improve exercise capacity and quality of life in patients with PAH.
Regional analysis of Pulmonary Arterial Hypertension Market
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)
๐๐๐๐ ๐๐จ๐ซ๐ ๐๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง? ๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐จ๐ฎ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ + ๐๐ซ๐๐ฉ๐ก๐ฌ ๐๐๐ซ๐:https://www.maximizemarketresearch.com/request-sample/122335/
Pulmonary Arterial Hypertension Market Segmentation
by Drug Class
Endothelin Receptor Antagonists
SGC Stimulators
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
Others
by Route of Administration
Oral
Intravenous
Others
by Type
Innovative
Generics
by Distribution Channel
Hospitals
Retail Pharmacies
Online Pharmacies
๐๐ฎ๐ซ๐ข๐จ๐ฎ๐ฌ ๐ญ๐จ ๐ฉ๐๐๐ค ๐ข๐ง๐ฌ๐ข๐๐? ๐๐ซ๐๐ ๐ฒ๐จ๐ฎ๐ซ ๐ฌ๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐ญ๐ก๐ข๐ฌ ๐ซ๐๐ฉ๐จ๐ซ๐ญ ๐ง๐จ๐ฐ:https://www.maximizemarketresearch.com/request-sample/122335/
Pulmonary Arterial Hypertension Market leaders
North America
United Therapeutics Corporation (USA)
Gilead Sciences (USA)
Pfizer Inc. (USA)
Arena Pharmaceuticals (USA)
Acceleron Pharma (USA)
Bristol Myers Squibb (USA)
Merck & Co. (USA)
Reata Pharmaceuticals (USA)
Stealth BioTherapeutics (USA)
Europe
Actelion Pharmaceuticals (Switzerland)
Bayer Healthcare:(Germany)
GlaxoSmithKline (GSK)(United Kingdom)
Novartis (Switzerland)
๐๐ง๐จ๐ฐ ๐๐จ๐ซ๐ ๐๐๐จ๐ฎ๐ญ ๐๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ:https://www.maximizemarketresearch.com/market-report/pulmonary-arterial-hypertension-market/122335/
Key questions answered in the Pulmonary Arterial Hypertension Market are:
What segments are covered in the Global Pulmonary Arterial Hypertension Market report?
Which region is expected to hold the highest share in the Global Pulmonary Arterial Hypertension Market?
What is the market size of the Global Market by 2030?
What is the forecast period for the Global Market?
What was the market size of the Global Pulmonary Arterial Hypertension Market in 2023?
Key Offerings:
Past Pulmonary Arterial Hypertension Market Size and Competitive Landscape (2018 to 2022)
Past Pricing and price curve by region (2018 to 2022)
Pulmonary Arterial Hypertension Market Size, Share, Size & Forecast by Different Segment | 2024-2030
Market Dynamics - Growth Drivers, Restraints, Opportunities, and Key Trends by Region
Market Segmentation - A detailed analysis by segment with their sub-segments and Region
Competitive Landscape - Profiles of selected key players by region from a strategic perspective
Competitive landscape - Market Leaders, Market Followers, Regional player
Competitive benchmarking of key players by region
PESTLE Analysis
PORTER's analysis
Value chain and supply chain analysis
Legal Aspects of Business by Region
Lucrative business opportunities with SWOT analysis
Recommendations
Maximize has also published reports on
โฆ Gate Driver IC Market https://www.maximizemarketresearch.com/market-report/gate-driver-ic-market/126324/
โฆ Global Hardware in the Loop Market (HIL) https://www.maximizemarketresearch.com/market-report/global-hardware-in-the-loop-market/22511/
โฆ India PVC Pipes Market https://www.maximizemarketresearch.com/market-report/india-pvc-pipes-market/21311/
โฆ Global B2B Telecommunication Market https://www.maximizemarketresearch.com/market-report/global-b2b-telecommunication-market/63857/
โฆ Tattoo Ink Market https://www.maximizemarketresearch.com/market-report/global-tattoo-ink-market/27167/
โฆ Microseismic Monitoring Technology Market https://www.maximizemarketresearch.com/market-report/global-microseismic-monitoring-technology-market/44398/
โฆ Electronic Data Interchange (EDI) Market https://www.maximizemarketresearch.com/market-report/global-electronic-data-interchange-edi-market/90413/
โฆ India Lubricants Market https://www.maximizemarketresearch.com/market-report/india-lubricants-market/29978/
โฆ Corporate Event Market https://www.maximizemarketresearch.com/market-report/corporate-event-market/148291/
MAXIMIZE MARKET RESEARCH PVT. LTD.
โฎ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
โ +91 9607365656
๐ sales@maximizemarketresearch.com
๐ www.maximizemarketresearch.com
About Maximize Market Research
Maximize Market Research is a global Market research and consulting company that provides businesses with insights to foster their growth and competitive advantage. The company specializes in delivering actionable and data-driven research reports tailored to help organizations make informed decisions. With a team of experienced analysts and consultants, Maximize Market Research offers expertise across multiple industries, including healthcare, technology, manufacturing, consumer goods, and more. Their services cover Market sizing, forecasting, competitive analysis, and customer insights, helping clients to address their strategic needs and identify emerging trends. The company emphasizes client success, offering detailed analysis and recommendations that support business transformation and operational excellence. Maximize Market Research also provides custom research services, allowing businesses to get solutions specific to their Market challenges. With a strong global presence, the company serves clients from various sectors, ensuring they stay ahead in a rapidly evolving Market landscape.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Market is expected to show growth from 2024 to 2030, reported by Maximize Market Research here
News-ID: 3677225 • Views: โฆ
More Releases from MAXIMIZE MARKET RESEARCH PVT. LTD.
Bangladesh Ceramics Tiles Market to Surpass USD 2.1 Billion by 2030, Fueled by a โฆ
Bangladesh Ceramics Tiles Market size was valued at USD 882.56 Million in 2023 and the total Bangladesh Ceramics Tiles Market revenue is expected to grow at a CAGR of 13.71 % from 2024 to 2030, reaching nearly USD 2169.38 Million.
Bangladesh Ceramics Tiles Market Overview:
The Bangladesh ceramics tiles market is a vital component of the country's construction and building materials industry, driven by rapid urbanization, infrastructure development, and rising disposable incomes.โฆ
Furfural Market to Reach Nearly USD 1 Trillion by 2030, Propelled by a 6.8% CAGR
Furfural Market size was valued at USD 630.2Mn in 2023. The Furfural Market revenue is growing at a CAGR of 6.8 % from 2023 to 2029, reaching nearly USD 998.30 Bn by 2030.
Furfural Market Overview:
The furfural market is centered around an organic compound derived primarily from agricultural byproducts such as corn cobs, sugarcane bagasse, and rice husks through a process of acid hydrolysis. As one of the oldest renewable chemicals,โฆ
Chemical Protective Clothing Market Valued at USD 1.57 Bn in 2024, Projected to โฆ
Chemical Protective Clothing Market size was valued at USD 1.57 Billion in 2024 and the total Chemical Protective Clothing revenue is expected to grow at a CAGR of 5.59% from 2025 to 2032, reaching nearly USD 2.42 Billion.
Chemical Protective Clothing Market Overview:
The Chemical Protective Clothing (CPC) market comprises garments and accessories specifically designed to shield workers from exposure to hazardous chemicals, liquids, and particulate matter across a wide range ofโฆ
Prefabricated Homes Market Valued at USD 18.58 Bn in 2024, Poised for 6.19% CAGR โฆ
Prefabricated Homes Market size was valued at USD 18.58 Billion in 2024 and the total Prefabricated Homes revenue is expected to grow at a CAGR of 6.19% from 2025 to 2032, reaching nearly USD 30.04 Billion.
Prefabricated Homes Market Overview:
The prefabricated homes market, also known as modular or off-site construction, involves the manufacturing of building components in a controlled factory environment before their assembly at the final location. This method revolutionizesโฆ
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary โฆ
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offersโฆ
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demandโฆ
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOCโฆ
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend ofโฆ
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market โ Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treatedโฆ
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic โฆ
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segmentsโฆ
